|Bid||16.38 x 1000|
|Ask||17.31 x 800|
|Day's Range||16.32 - 17.04|
|52 Week Range||14.48 - 31.54|
|Beta (5Y Monthly)||1.17|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Theravance (TBPH) falls more than 13% as it reports wider-than-expected loss for the third quarter of 2020. Revenues meet estimates.
Last week, you might have seen that Theravance Biopharma, Inc. (NASDAQ:TBPH) released its quarterly result to the...
Good day, good afternoon, and thank you for joining the Theravance Biopharma quarterly conference call to discuss our business. Joining us are Rick Winningham, Chief Executive Officer; followed by Frank Pasqualone; Chief Commercial Operations Officer; Brett Haumann, Chief Medical Officer; and Andrew Hindman, Chief Financial Officer.